 Cytochrome P-450 CYP3A
"Cytochrome P-450 CYP3A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 monooxygenase that is involved in an NADPH-dependent electron transport pathway by oxidizing a variety of structurally unrelated compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN.
| Descriptor ID |
D051544
|
| MeSH Number(s) |
D08.244.453.040.986 D08.811.682.662.582.353 D08.811.682.690.708.170.040.888 D12.776.422.220.453.040.972
|
| Concept/Terms |
Cytochrome P-450 CYP3A- Cytochrome P-450 CYP3A
- Cytochrome P 450 CYP3A
- P-450 CYP3A, Cytochrome
- Erythromycin N-Demethylase
- Erythromycin N Demethylase
- N-Demethylase, Erythromycin
- Cytochrome P450 3A
- P450 3A, Cytochrome
- CYP3A
- Cytochrome P-450IIIA
- Cytochrome P 450IIIA
- P-450IIIA, Cytochrome
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A" by people in UAMS Profiles by year, and whether "Cytochrome P-450 CYP3A" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 | | 2020 | 1 | 2 | 3 | | 2019 | 3 | 1 | 4 | | 2018 | 0 | 2 | 2 | | 2017 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2014 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2010 | 2 | 1 | 3 | | 2009 | 2 | 0 | 2 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 | | 2006 | 1 | 4 | 5 | | 2004 | 0 | 3 | 3 | | 2003 | 0 | 4 | 4 | | 2002 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 1999 | 0 | 2 | 2 | | 1994 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP3A" by people in Profiles over the past ten years.
-
Haigentz M, Lee JY, Chiao EY, Aboulafia DM, Ratner L, Ambinder RF, Baiocchi RA, Mitsuyasu RT, Wachsman W, Sparano JA, Rudek MA. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Clin Cancer Res. 2023 12 15; 29(24):5038-5046.
-
Kamble SH, Obeng S, Le?n F, Restrepo LF, King TI, Berthold EC, Kanumuri SRR, Gamez-Jimenez LR, Pallares VLC, Patel A, Ho NP, Hampson A, McCurdy CR, McMahon LR, Wilkerson JL, Sharma A, Hiranita T. Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats. J Pharmacol Exp Ther. 2023 06; 385(3):180-192.
-
Schleiff MA, Crosby S, Blue M, Schleiff BM, Boysen G, Miller GP. CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochem Pharmacol. 2021 12; 194:114824.
-
Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacol Biochem Behav. 2020 08; 195:172949.
-
Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). Pharmacol Res Perspect. 2020 02; 8(1):e00561.
-
McCullough S, Dweep H, McGill MR, Bhattacharyya S, James L, Frankowski S, Woodall A, Kearns G, Gill P. Granzyme B and miR-378a Interaction in Acetaminophen Toxicity in Children. Microrna. 2020; 9(2):121-132.
-
Barnette DA, Davis MA, Flynn N, Pidugu AS, Swamidass SJ, Miller GP. Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation. Biochem Pharmacol. 2019 12; 170:113661.
-
Davis MA, Barnette DA, Flynn NR, Pidugu AS, Swamidass SJ, Boysen G, Miller GP. CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches. Chem Res Toxicol. 2019 06 17; 32(6):1151-1164.
-
Kazuki Y, Kobayashi K, Hirabayashi M, Abe S, Kajitani N, Kazuki K, Takehara S, Takiguchi M, Satoh D, Kuze J, Sakuma T, Kaneko T, Mashimo T, Osamura M, Hashimoto M, Wakatsuki R, Hirashima R, Fujiwara R, Deguchi T, Kurihara A, Tsukazaki Y, Senda N, Yamamoto T, Scheer N, Oshimura M. Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism. Proc Natl Acad Sci U S A. 2019 02 19; 116(8):3072-3081.
-
Reed L, Indra R, Mrizova I, Moserova M, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM. Application of hepatic cytochrome b5/P450 reductase null (HBRN) mice to study the role of cytochrome b5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine. Toxicol Appl Pharmacol. 2019 03 01; 366:64-74.
-
Guimbellot JS, Acosta EP, Rowe SM. Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 05; 53(5):E6-E8.
-
Willis AJ, Indra R, Wohak LE, Sozeri O, Feser K, Mrizova I, Phillips DH, Stiborova M, Arlt VM. The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/-) and TP53(-/-) cells. Toxicology. 2018 04 01; 398-399:1-12.
-
Gill P, Bhattacharyya S, McCullough S, Letzig L, Mishra PJ, Luo C, Dweep H, James L. MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity. Sci Rep. 2017 09 26; 7(1):12331.
-
Haarhoff ZE, Kramer MA, Zvyaga TA, Zhang J, Bhutani P, Subramanian M, Rodrigues AD. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human. Xenobiotica. 2017 Jun; 47(6):470-478.
-
Shakhnovich V, Vyhlidal C, Friesen C, Hildreth A, Singh V, Daniel J, Kearns GL, Leeder JS. Decreased Pregnane X Receptor Expression in Children with Active Crohn's Disease. Drug Metab Dispos. 2016 07; 44(7):1066-9.
-
Giebel NL, Shadley JD, McCarver DG, Dorko K, Gramignoli R, Strom SC, Yan K, Simpson PM, Hines RN. Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny. Drug Metab Dispos. 2016 07; 44(7):1027-37.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|